In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
